Daflon 500mg達夫隆

Daflon 500mg

diosmin + hesperidin

Manufacturer:

Servier

Distributor:

Zuellig
/
The Glory Medicina
Full Prescribing Info
Contents
Micronized, purified flavonoid fraction.
Description
Each coated tablet contains micronized flavonoid fraction 500 mg (diosmin 450 mg and flavonoids expressed as hesperidin 50 mg). Daflon 500mg also contains the following excipients: Carboxymethylcellulose sodium, microcrystalline cellulose, gelatin, magnesium stearate, talc, white beeswax, glycerol, hydroxypropyl methylcellulose (2910), polyethylene glycol 6000, sodium lauryl sulfate, yellow iron oxide, red iron oxide and titanium dioxide.
The innovation with Daflon 500mg consists of the micronization of its active constituent from particles of 15-40 microns to particles of <2 microns. Micronization of Daflon 500mg increases gastrointestinal absorption compared to nonmicronized diosmin (urinary 57.9% vs 32.7%). This new and optimized form allows a better absorption of Daflon 500mg thus better bioavailability and consequently a more rapid onset of efficacy from the first 2-tablet dose and by the 1st hour and provides Daflon 500mg with added clinical efficacy.
Action
Daflon 500mg is a phlebotonic drug and a vascular protecting agent. The efficacy of Daflon 500mg is accounted for by its specific action on the principal elements of venous disease.
Daflon 500mg is phlebotonic: It reinforces venous tone by prolonging the activity of parietal noradrenaline. Thus, Daflon 500mg decreases venous capacitance, venous distensibility and venous emptying time.
Daflon 500mg protects the microcirculation by fighting the microcirculation-damaging process; it combats venous inflammation by decreasing leukocyte activation, and as a consequence, by inhibiting the release of inflammatory mediators, principally free radicals and prostaglandins. Thus, Daflon 500mg normalizes capillary permeability and strengthens capillary resistance.
Daflon 500mg acts on the lymphatic system. It improves lymphatic drainage by increasing lymph flow and lymph oncotic pressure. This action on the lymphatic system associated with a phlebotonic and vasculoprotective effect, explains the activity of Daflon 500mg on CVI-associated edema.
Double-blind, placebo-controlled studies have demonstrated that Daflon 500mg is effective on chronic venous insufficiency. Daflon 500mg significantly improves disabling symptoms of venous insufficiency which affect everyday active life: Heavy legs, pain, heat sensation, edema, functional impairment, nocturnal cramps. In addition to conventional compression therapy, Daflon 500mg has also demonstrated to cure 3 times as many venous leg ulcers as placebo, and to accelerate their complete healing.
Daflon 500mg is highly effective in the treatment of chronic hemorrhoidal disease. It significantly improves subjective symptoms and objective signs eg, anal discomfort, pain, redness, anal discharge, proctitis, tenesmus, pruritus, erythema and bleeding. Daflon 500mg also significantly reduces the frequency, severity and duration of acute hemorrhoidal attacks by a chronic treatment.
Indications/Uses
Treatment of the symptoms and signs of organic and functional chronic venous insufficiency of the lower limbs eg, heavy legs, pain, heat sensation, edema, functional impairment, nocturnal cramps.
Treatment of the symptoms of acute hemorrhoidal attacks and chronic hemorrhoidal disease.
Dosage/Direction for Use
Usual Dose: Chronic Venous Insufficiency: 2 tablets daily with meals. Chronic Hemorrhoidal Disease: 2 tablets daily with meals. Acute Hemorrhoidal Attack: 6 tablets daily (in 2 divided doses) for 4 days, then 4 tablets daily (in 2 divided doses) for 3 days, 2 tablets thereafter.
Contraindications
None.
Special Precautions
Use in pregnancy: Experimental studies have not shown any teratogenic effect in animals. In human beings, no harmful effect has so far been reported.
Use in lactation: In the absence of data concerning the diffusion into breast milk, breastfeeding is not recommended during treatment.
Use In Pregnancy & Lactation
Use in pregnancy: Experimental studies have not shown any teratogenic effect in animals. In human beings, no harmful effect has so far been reported.
Use in lactation: In the absence of data concerning the diffusion into breast milk, breastfeeding is not recommended during treatment.
Adverse Reactions
Some cases of minor gastrointestinal and neurovegetative disorders have been reported, which never required cessation of treatment.
Drug Interactions
None.
Incompatibilities: None.
Storage
Store at room temperature below 30°C.
ATC Classification
C05CA53 - diosmin, combinations ; Belongs to the class of bioflavonoids used as capillary stabilizing agents.
Presentation/Packing
Coated tab 30's.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in